Cancer Res. 2022 May 3;82(9):1682-1688. doi: 10.1158/0008-5472.CAN-21-4044.
Cancer cells are demarcated from normal cells by distinct biological hallmarks, including the reprogramming of metabolic processes. One of the key players involved in metabolic reprogramming is stearoyl-CoA desaturase (SCD), which converts saturated fatty acids to monounsaturated fatty acids in an oxygen-dependent reaction that is crucial for maintaining fatty acid homeostasis. As such, SCD has been identified as a potential therapeutic target in numerous types of cancers, and its inhibition suppresses cancer cell growth in vitro and in vivo. This review summarizes the evidence implicating SCD in cancer progression and proposes novel therapeutic strategies for targeting SCD in solid tumors.
癌细胞与正常细胞通过独特的生物学特征区分开来，包括代谢过程的重编程。参与代谢重编程的关键分子之一是硬脂酰辅酶 A 去饱和酶（SCD），它在氧气依赖的反应中将饱和脂肪酸转化为单不饱和脂肪酸，对于维持脂肪酸的体内平衡至关重要。因此，SCD 已被确定为许多类型癌症的潜在治疗靶点，其抑制作用可抑制体外和体内癌细胞的生长。本综述总结了 SCD 参与癌症进展的证据，并提出了针对实体瘤中 SCD 的新的治疗策略。
